Rachid Izzar - Jul 22, 2021 Form 3 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Alzheimer's Disease
Signature
/s/ Suzanne Murray, attorney-in-fact for Rachid Izzar
Stock symbol
BIIB
Transactions as of
Jul 22, 2021
Transactions value $
$0
Form type
3
Date filed
7/29/2021, 04:18 PM
Next filing
Dec 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIIB Common Stock 899 Jul 22, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIIB Restricted Stock Unit Jul 22, 2021 Common Stock 1.71K $0.00 Direct F1
holding BIIB Restricted Stock Unit Jul 22, 2021 Common Stock 2.01K $0.00 Direct F2
holding BIIB Restricted Stock Unit Jul 22, 2021 Common Stock 4.35K $0.00 Direct F3
holding BIIB Restricted Stock Unit Jul 22, 2021 Common Stock 1.29K $0.00 Direct F4
holding BIIB Restricted Stock Unit Jul 22, 2021 Common Stock 1.01K $0.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This award was granted to the reporting person on December 2, 2019. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2 This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F3 This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F4 This award was granted to the reporting person on December 2, 2019, and will vest in full on December 2, 2022.
F5 This award was granted to the reporting person on July 1, 2020, and will vest in three equal installments on each anniversary of the grant date.